Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Xu discussed the benefit of using biomarkers to more precisely guide treatment for patients with renal cell carcinoma.

The incidence of hepatocellular carcinoma has risen between 2010 and 2019; however, for people under 50 years of age, the proportion of cases has declined.

I wrote a poem about life with endometrial cancer, rejecting pity and embracing strength, connection and the dignity of being ...

Dena Paluck became a mentor to other parents after guiding her daughter through osteosarcoma treatment and feeling isolated ...

Among individuals who receive a cancer diagnosis, entering into the survivorship period can be one of the most ...

I survived peritoneal mesothelioma thanks to the love, prayers, and support of family, friends, and strangers who reminded me ...

In a phase 3 trial, 72.2% of patients with recurrent low-grade bladder cancer kept complete response at 24 months after ...

Getting an expert opinion is essential after a rare cancer diagnosis like GIST, as each patient’s situation is unique, ...

The U.S. FDA granted accelerated approval to Modeyso for the patients with diffuse midline glioma with an H3 K27M mutation ...

Following the June 2025 FDA approval of Datroway, Dr. Jacob A. Sands explained the significance of the regulatory approval ...

In an interview with CURE, Clara Cirk shares the emotional weight of finishing chemo while facing ongoing immunotherapy and ...